[go: up one dir, main page]

WO2016072500A1 - Assemblage moléculaire contenant de l'arn modifié, et système d'administration de l'arn à l'aide de ce dernier - Google Patents

Assemblage moléculaire contenant de l'arn modifié, et système d'administration de l'arn à l'aide de ce dernier Download PDF

Info

Publication number
WO2016072500A1
WO2016072500A1 PCT/JP2015/081352 JP2015081352W WO2016072500A1 WO 2016072500 A1 WO2016072500 A1 WO 2016072500A1 JP 2015081352 W JP2015081352 W JP 2015081352W WO 2016072500 A1 WO2016072500 A1 WO 2016072500A1
Authority
WO
WIPO (PCT)
Prior art keywords
rna
molecular assembly
seq
sirna
polylactic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2015/081352
Other languages
English (en)
Japanese (ja)
Inventor
高史 大槻
栄次 松浦
浩嗣 小渕
彰也 赤星
英一 小関
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shimadzu Corp
Okayama University NUC
Original Assignee
Shimadzu Corp
Okayama University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimadzu Corp, Okayama University NUC filed Critical Shimadzu Corp
Priority to JP2016557827A priority Critical patent/JP6586103B2/ja
Publication of WO2016072500A1 publication Critical patent/WO2016072500A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Definitions

  • the present invention belongs to the technical fields of life science, biotechnology, and clinical medicine.
  • the present invention relates to a molecular assembly containing a polymer-modified RNA, a therapeutic agent containing the same, an RNA delivery system using the same, and the like.
  • Nucleic acid pharmaceuticals that are a kind of water-soluble drug and have a nucleic acid such as DNA or RNA in their skeleton, because they bind to and act on specific base sequences on genes, and thus have been difficult to treat. It is expected to be applied to cancer and genetic diseases. Conventional low molecular weight compounds need to select candidate compounds that bind to a specific target, and therefore have an excessive effort in compound search, and the market probability is only about 1 / 30,000. On the other hand, nucleic acid drugs are considered to be more versatile than low molecular weight compounds because they can directly target disease-related genes themselves and suppress the expression of disease-causing proteins.
  • SiRNA small interfering RNA
  • DDS drug delivery system
  • RNA As a DDS technique for delivering functional RNA such as siRNA into cells, a technique of encapsulating RNA in a cationic liposome is known (for example, see Patent Document 1). Cationic liposomes can form a complex easily by electrostatic interaction with negatively charged RNA because their constituent lipids are positively charged, and the complex fuses with the cell membrane. At the same time, RNA is thought to enter the cell. Similarly to cationic liposomes, DDS technology is also known in which a cationic polymer and RNA are bound by electrostatic interaction and RNA is introduced into cells (see, for example, Patent Document 2).
  • RNA and cationic polymer are problematically inhibited by anionic molecules (such as sulfated polysaccharides) and cationic molecules in the living body, and the cationic polymer itself is intracellular. In general, it has the ability to adhere to and enter cells, and is generally highly cytotoxic.
  • anionic molecules such as sulfated polysaccharides
  • cationic polymer itself is intracellular. In general, it has the ability to adhere to and enter cells, and is generally highly cytotoxic.
  • nano-level polymer micelles composed of an amphiphilic block polymer composed of a hydrophobic polylactic acid chain and a hydrophilic polysarcosine chain have been proposed as being capable of exhibiting an excellent DDS effect.
  • a linear amphiphilic block polymer in which a hydrophobic block is a polylactic acid chain and a hydrophilic block is a polysarcosine chain is self-assembled in an aqueous solution, and the particle size is reduced. It is disclosed to form polylactic acid-sarcosine polymer micelles of 30 nm or more.
  • Non-Patent Document 4 discloses a polylactic acid-sarcosine polymer micelle comprising a linear amphiphilic block polymer in which the hydrophobic block is a poly L-lactic acid (PLLA) chain and the hydrophilic block is a polysarcosine chain.
  • 3 kinds of indocyanine green (ICG) -labeled polylactic acid ICG-PLLA, ICG-PDLA, and ICG-PDLLA are respectively included in the three polylactic acid-sarcosine polymer micelles. It is disclosed that it has been prepared, and the behavior exerted by the stereochemistry of ICG-labeled polylactic acid in vivo is disclosed.
  • the particle diameter of the polymer micelle used in Non-Patent Document 4 is 35 nm or more.
  • Polylactic acid-sarcosine polymer micelles using linear amphiphilic block polymers disclosed in Patent Document 3 and Non-Patent Documents 3 and 4 have high blood retention and have been developed so far. It has been reported that the amount of accumulation in the liver is remarkably reduced compared to the polymer micelles.
  • these polylactic acid-sarcosine polymer micelles can be used in tumor (cancer) tissues in which nanoparticles with a particle size of several tens to several hundreds of nanometers staying in the blood are remarkably enhanced.
  • EPR effect Enhanced Permeation and Retention effect
  • Patent Document 4 discloses a molecular assembly formed by self-organizing an amphiphilic block polymer by designing the molecule so that the hydrophilic block has a branched structure composed of a plurality of sarcosine chains. Is disclosed. Patent Document 4 discloses functionalization of a molecular assembly by blending a functional substance having a polylactic acid chain, and a particle size control technique by blending a linear amphiphilic polymer into the molecular assembly. Has been.
  • Patent Document 5 discloses a branched amphiphilic block polymer A having a branched hydrophilic block containing a sarcosine chain and a hydrophobic block having a polylactic acid chain, and a functional part having a functional site and a polylactic acid chain.
  • a molecular assembly containing substance F is disclosed.
  • the polylactic acid chain constituting the hydrophobic block of the amphiphilic block polymer A is composed of L-lactic acid units, and the polylactic acid chain contained in the functional substance F is D-lactic acid.
  • a polylactic acid chain constituting the hydrophobic block of the amphiphilic block polymer A is composed of a D-lactic acid unit, and the polylactic acid chain contained in the functional substance F is L-lactic acid. It consists of units.
  • Patent Documents 3 to 5 and the like do not specifically describe intracellular delivery of RNA. That is, it is unclear whether the molecular assemblies described in Patent Documents 3 to 5 are effective for intracellular delivery of RNA.
  • RNA-binding protein a carrier protein containing a cell membrane permeable peptide (CPP) and an RNA-binding protein (RBP) was linked to the N-terminal side or C-terminal side of the carrier protein.
  • Carrier molecules having a structure composed of a photosensitizer (PST) that functions with light having a wavelength in the near infrared region have been proposed (see Patent Document 6).
  • PST photosensitizer
  • the RNA complex is diffused into the cytoplasm and the function of RNA is expressed.
  • This technique causes RNA to enter the cytoplasm and express its function, but even if the RNA complex is administered into the living body, it may be immediately degraded by a degrading enzyme (RNase) in the body.
  • RNase degrading enzyme
  • RNA cell membrane-permeable peptide
  • a nanoparticle such as a molecular assembly
  • RNA is encapsulated in the nanoparticle
  • the RNA is effectively diffused into cells by irradiating the photosensitizer with light.
  • the nanoparticles have a blocking action to such an extent that degradation by in-vivo enzymes can be suppressed while RNA is delivered to the cancer tissue.
  • the present invention provides a novel molecular assembly containing a functional RNA that enables introduction of a functional RNA such as siRNA or shRNA into a cell and delivery to a disease site by in vivo administration. This is the main issue.
  • Another object of the present invention is to provide a cancer preventive or therapeutic agent containing the molecular assembly, an RNA delivery system using the molecular assembly, and the like.
  • a DDS mainly composed of an amphiphilic block polymer A having a hydrophilic block containing a sarcosine chain and a hydrophobic block containing a lactic acid chain. It has been found that the above problems can be solved by including RNA modified with a long-chain compound having a hydrophobic group, a cell membrane-binding compound, and a photosensitizer in a carrier, thereby completing the present invention. It came.
  • Examples of the present invention include the following.
  • a molecular assembly comprising the following components 1 to 4 as essential components.
  • Amphiphilic block polymer A having a hydrophilic block containing a sarcosine chain and a hydrophobic block containing a lactic acid chain 2) RNA modified with a compound having a long hydrophobic group 3) Cell membrane-binding compound 4) A photosensitizer that may be bound to one or more of the above components 1 to 3.
  • amphiphilic block polymer A has a hydrophilic block containing 20 to 300 sarcosine units and a hydrophobic block containing 10 to 100 lactic acid units. Molecular assembly.
  • RNA having a gene expression suppressing effect is siRNA, shRNA, miRNA, antisense RNA, aptamer RNA, or ribozyme.
  • siRNA is an siRNA that knocks down the ATP-binding cassette transporter G2 (ABCG2) gene, suppresses its expression, knocks down the ferrokeratase gene, and inhibits its activity, or a combination of both
  • ABCG2 ATP-binding cassette transporter G2
  • the molecular assembly according to [7] above, wherein the siRNA that knocks down the ABCG2 gene and suppresses its expression is a double-stranded nucleic acid comprising the following sense strand and antisense strand.
  • Sense strand (SEQ ID NO: 10): 5'-CGAUAUGGAUUUACGGGCUUdTdT-3 '
  • Antisense strand (SEQ ID NO: 11): 5'-AAGCCCGUAAAUCCAUAUCGdTdG-3 ' [9]
  • the molecular assembly according to [7] above, wherein the siRNA that knocks down the ferrochelatase gene and inhibits its activity is a double-stranded nucleic acid consisting of the following sense strand and antisense strand.
  • Sense strand (SEQ ID NO: 12): 5′-GCAUUUACCAGUGACCACCAUadTdT-3 ′
  • Antisense strand (SEQ ID NO: 13): 5'-UAUGGUCACUUGGUAAAAUGCdTdA-3 '
  • a cell membrane permeable peptide is SEQ ID NO: 1: GALFLGFLGAAGSTMGAWSQPKKRKRKV SEQ ID NO: 2: YGRKKRRQRRRG SEQ ID NO: 3: RRRRNRTRRNRRRVR SEQ ID NO: 4: YGRRRRRRRRR Sequence number 5: KETWWETWWTE SEQ ID NO: 14: RKKRRRESRKKRRRESC SEQ ID NO: 15: YARAAARQARAC SEQ ID NO: 16: KETWETWWTEWSQPKKKKRKVC, or SEQ ID NO: 17: LIRLWSHLIHIWFQNRRLKWKKC The molecular assembly according to [10] above.
  • Photosensitizers that function with light having a wavelength of 450 nm to 1300 nm include cyanine dyes such as fluorescein dyes and indocyanine dyes, rhodamine dyes, porphyrin dyes, Alexa Fluor (registered trademark) 546, Alexa
  • a system for delivering RNA into a tumor cytoplasm comprising using the molecular assembly according to any one of [1] to [14] above.
  • a preventive or therapeutic agent for cancer comprising the molecular assembly according to any one of [1] to [14].
  • RNA modified with a polymer having polylactic acid or polylactic acid / polysarcosine copolymer [20] The RNA according to [19] above, wherein the RNA has a gene expression suppressing effect. [21] The RNA according to [20] above, wherein the RNA having a gene expression inhibitory effect is siRNA, shRNA, miRNA, antisense RNA, aptamer RNA, or ribozyme.
  • siRNA is a siRNA that knocks down the ATP-binding cassette transporter G2 (ABCG2) gene, suppresses its expression, knocks down the ferrokeratase gene, and inhibits its activity, or a combination of both The RNA according to [21], which is a product.
  • the RNA according to [22] above, wherein the siRNA that knocks down the ABCG2 gene and suppresses its expression is a double-stranded nucleic acid comprising the following sense strand and antisense strand.
  • Sense strand (SEQ ID NO: 10): 5'-CGAUAUGGAUUUACGGGCUUdTdT-3 '
  • Antisense strand (SEQ ID NO: 11): 5'-AAGCCCGUAAAUCCAUAUCGdTdG-3 ' [24]
  • the RNA according to [22] above, wherein the siRNA that knocks down the ferrochelatase gene and inhibits its activity is a double-stranded nucleic acid comprising the following sense strand and antisense strand.
  • Sense strand (SEQ ID NO: 12): 5′-GCAUUUACCAGUGACCACCAUadTdT-3 ′
  • Antisense strand (SEQ ID NO: 13): 5'-UAUGGUCACUUGGUAAAAUGCdTdA-3 '
  • RNA modified with a compound having a long hydrophobic group (hereinafter also simply referred to as “modified RNA”) is converted into a hydrophilic block containing a sarcosine chain and a hydrophobic block containing a lactic acid chain.
  • modified RNA is converted into a hydrophilic block containing a sarcosine chain and a hydrophobic block containing a lactic acid chain.
  • the molecular assembly can be adsorbed, and accordingly the molecular assembly can be effectively incorporated into the endosome, and when the photosensitizer contained in the molecular assembly is irradiated with light, Thus, the collapse of the molecular assembly and the intracellular diffusion of the RNA can occur almost simultaneously. In addition, the influence of the enzyme in the body can be suppressed from the administration of the carrier into the blood until the light is irradiated.
  • the molecular assembly mainly composed of the amphiphilic block polymer A is also called Lactosome (registered trademark), and is known, for example, in Patent Documents 3 to 4, and the present invention can enjoy its usefulness. . That is, since the molecular assembly mainly composed of the amphiphilic block polymer A has a size of several tens of nanometers, it has a high accumulation property in affected tissue such as cancer tissue, and conversely to other tissues. Since it is composed of biodegradable components, it is highly safe for living bodies. In addition, particle size control is easy and preparation is easy.
  • the modified RNA according to the present invention is basically encapsulated in a micelle assembly by a hydrophobic interaction based on a hydrophobic modification moiety, not by an electrostatic interaction such as binding to a cationic polymer. . Therefore, the molecular assembly of the present invention is hardly inhibited by an anionic molecule (such as a sulfated polysaccharide) or a cationic molecule in the living body.
  • the cationic polymer itself has the ability to adhere to and invade cells and is generally highly cytotoxic, but it can be avoided.
  • the molecular assembly of the present invention can diffuse and deliver RNA into the cytoplasm, and can exhibit the function of RNA (gene expression suppression function).
  • RNA can be delivered and accumulated in an affected tissue such as a tumor effectively and safely by in vivo administration (accumulation in other tissues can be suppressed and side effects can be reduced), and The function of RNA can be exhibited in the cytoplasm of the affected tissue.
  • FIG. 1 It is a schematic diagram showing a mode when the molecular assembly of the present invention moves into the cytoplasm. It is a synthetic
  • the upper figure on the left represents a polylactic acid / polysarcosine copolymer to which a maleimide group is bonded, and the upper figure on the right represents siRNA.
  • the siRNAs on the right in the above figure the one to which the thiol group (HS-group) is bonded is the sense strand, and the other is the antisense strand. Represents an electropherogram.
  • Line 1 is for RNA only
  • line 2 is for RNA / polymer blend ratio of 1: 2
  • line 3 is for blend ratio of 1: 5
  • line 2 is for blend The case where the ratio is 1:10 is shown.
  • It is an electrophoretic diagram before and after purification of siRNA / polymer reaction product. It represents the knockdown effect (RNAi effect) of EGFP.
  • the left column shows the control
  • the middle column shows the result of introducing the target sequence siRNA into the cell
  • the right column shows the result of the introduction of the non-target sequence modified siRNA into the cell. Show. It represents the knockdown effect (RNAi effect) of EGFP.
  • the left column is an untreated negative control for EGFP-CHO cells
  • the second column from the left is a negative control to which only the introduction reagent (lipofectamine) is administered
  • the right column is an anti-EGFP sequence unmodified siRNA.
  • the positive control administered, the second column from the right show the results of administration of anti-EGFP sequence DMT-C6-SS-C6-modified siRNA, respectively.
  • transduction cell is represented. 3 on the left represents the results in 211H cells, and FIG. 3 on the right represents the results in CFPAC1 cells.
  • Each upper row shows the expression level of ABCG2, each middle row shows the expression level of ferrochelatase, and each lower row shows the expression level of actin. It is a histogram showing the amount of intracellular protoporphyrin IX (PpIX) accumulation.
  • the upper figure shows the results in 211H cells, and the lower figure shows the results in CFPAC1 cells.
  • the vertical axis represents the number of cells, and the horizontal axis represents the amount of intracellular PpIX.
  • control ( ⁇ ) ALA” represents a negative control administered with only the introduction reagent (lipofectamine)
  • control (+) ALA represents the result of treatment with the introduction reagent and ALA
  • ABCG2 represents ABCG2.
  • FECH shows the results of ferrochelatase siRNA introduction and treatment with ALA
  • ABCG2 + FECH shows the results of introduction of ABCG2 siRNA and FECH siRNA and treatment with ALA, respectively.
  • the change of the cell viability by photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) is represented.
  • the left figure shows the results in 211H cells, and the right figure shows the results in CFPAC1 cells.
  • the leftmost column is a negative control (control ( ⁇ ) ALA) administered with only the introduction reagent (lipofectamine), and the second column from the left is the result of treatment with the introduction reagent and ALA (control ( +) ALA), the third column from the left is the result of ABCG2 siRNA introduction and ALA treatment (ABCG2), the fourth column from the left is the result of ferrochelatase siRNA introduction and ALA treatment (FECH), The fifth column from the left shows the results of introduction of ABCG2 siRNA and ferrochelatase siRNA and treatment with ALA (ABCG2 + FECH), respectively.
  • ABCG2 ABCG2 siRNA introduction and ALA treatment
  • FECH ferrochelatase siRNA introduction and ALA treatment
  • the upper left photo shows the phase contrast image
  • the upper center shows the photo before the FAM-modified siRNA irradiation
  • the upper right photo shows the photo after the FAM-modified siRNA irradiation
  • the lower left shows the photo of the Alexa546-modified CPP peptide before the light irradiation.
  • the lower right shows the photo after light irradiation of Alexa546-modified CPP peptide.
  • the left end shows a photograph of a phase contrast image
  • the center shows a photograph before light irradiation of FAM-modified siRNA
  • the right end shows a photograph after light irradiation of FAM-modified siRNA.
  • the left end is a photo of the phase contrast image
  • the center is the photo before DMT-C6-SS-C6-modified siRNA labeled with FAM
  • the right end is irradiated with FAM-labeled DMT-C6-SS-C6-modified siRNA.
  • the following photos are shown respectively.
  • the molecular assembly of the present invention binds to an amphiphilic block polymer A having a hydrophilic block containing a sarcosine unit and a hydrophobic block containing a lactic acid unit, a modified RNA, a cell membrane-binding compound, and the one or more components.
  • the photosensitizer which may be included is included.
  • the molecular assembly of the present invention is usually a structure mainly formed by aggregation or self-assembly of the amphiphilic block polymer A or by self-assembled orientational association.
  • the form of the molecular assembly is not particularly limited, and includes all forms of particles such as micelles and vesicles, lamellar structures, rods, and other aggregated forms of molecules. Usually, it is particulate.
  • the preferable form of the molecular assembly of this invention is a micelle.
  • amphiphilic block polymer A includes a sarcosine unit in one hydrophobic block including a lactic acid unit even in a linear type in which a hydrophilic block including a sarcosine unit and a hydrophobic block including a lactic acid unit are linearly bonded.
  • a branched type in which the hydrophilic block is branched and bonded into three may be used.
  • the hydrophilic block and the hydrophobic block are usually connected by a linker site.
  • Amphiphilic block polymer A is known, and is described, for example, in Patent Documents 3 to 5, including the production method.
  • the amphiphilic block polymer A described in this patent document etc. can be used.
  • the entire contents described in Patent Documents 3 to 5 are referred to and incorporated herein.
  • the degree of the physical property “hydrophilic” of the hydrophilic block of the amphiphilic block polymer A is not particularly limited, but at least the entire hydrophilic block is a hydrophobic block described later. In contrast, it has a relatively strong hydrophilic property. Or hydrophilic property of the grade which becomes possible to implement
  • the hydrophilic block in the amphiphilic block polymer A has a polysarcosine chain.
  • Sarcosine N- methyl glycine
  • polymers of sarcosine than ordinary amide group because of their N-substituted amide cis - are possible trans isomerization, further, C alpha around carbon Since there is little steric hindrance, it has high flexibility.
  • the use of such a structure as a building block is very useful in that the block has basic characteristics with high hydrophilicity or basic characteristics having both high hydrophilicity and high flexibility.
  • the type and ratio of the structural unit can be appropriately determined by those skilled in the art so that the entire block is hydrophilic as described above.
  • the total number of sarcosine units contained in the hydrophilic block can usually be 20 to 300.
  • the number is preferably about 30 to 200, more preferably about 50 to 100.
  • the average number of sarcosine units per branch is, for example, 10 To 100, and preferably about 20 to 50.
  • the branched amphiphilic block polymer A can form a particulate molecular assembly.
  • the number of sarcosine units contained in the hydrophilic block is in such a range, when the molecular assembly is formed, the formed molecular assembly becomes stable.
  • the hydrophilic block may have one or more structural units other than the sarcosine unit as long as the hydrophilicity as described above is not impaired.
  • structural units other than sarcosine include amino acids.
  • the amino acid may be a natural amino acid or an unnatural amino acid.
  • the amino acid may be an ⁇ -amino acid, ⁇ -amino acid, or ⁇ -amino acid, but is preferably an ⁇ -amino acid, and examples thereof include serine, threonine, lysine, aspartic acid, and glutamic acid.
  • the proportion of structural units other than sarcosine units is usually 10 mol% or less, preferably 5 mol% or less, more preferably 2 mol% or less, and still more preferably 1 with respect to all the structural units constituting the hydrophilic block.
  • the mol% or less most preferably 0 mol%.
  • the hydrophilic block is preferably composed only of sarcosine units.
  • all the sarcosine units may be continuous or discontinuous, but the molecular structure is designed so as not to impair the basic characteristics of the amphiphilic block polymer A as a whole. Preferably there is.
  • the specific level of the physical property “hydrophobic” of the hydrophobic block is not particularly limited. However, at least the hydrophobic block is relative to the entire hydrophilic block. In other words, it is a region having a strong hydrophobicity, and it is sufficient that the copolymer molecule is formed so as to be amphiphilic as a whole by forming a copolymer with a hydrophilic block. Alternatively, it is only necessary that the amphiphilic block polymer A has a hydrophobicity that enables self-assembly in a solvent to form a self-assembly, preferably a particulate self-assembly.
  • the hydrophobic block in the amphiphilic block polymer A has a polylactic acid chain.
  • Polylactic acid has excellent biocompatibility and stability. For this reason, a molecular assembly formed from such an amphiphilic substance having polylactic acid as a building block is very useful in terms of applicability to a living body, particularly a human body.
  • polylactic acid has excellent biodegradability and thus is rapidly metabolized and has low accumulation in tissues other than tumor tissues in vivo. Therefore, a molecular assembly obtained from such an amphiphilic substance having polylactic acid as a building block is useful in terms of specific accumulation in tumor tissue.
  • polylactic acid is excellent in solubility in a low-boiling solvent
  • a harmful high-boiling solvent is used. It is possible to avoid use. For this reason, the molecular assembly of the present invention is useful in terms of safety to living bodies.
  • the polylactic acid chain contained in the hydrophobic block is usually not branched (linear).
  • the types and ratios of the structural units in the hydrophobic block are appropriately determined by those skilled in the art so that the entire block is hydrophobic as described above.
  • the number of lactic acid units contained in the hydrophobic block is usually 10 to 100, preferably about 20 to 80, more preferably about 25 to 50, and further preferably about 25 to 35. When the number of lactic acid units contained in the hydrophobic block is in the above range, the molecular assembly formed by the amphiphilic block polymer A becomes stable.
  • the hydrophobic block may have one or more structural units other than the lactic acid unit as long as the hydrophobicity as described above is not impaired.
  • the structural unit other than the lactic acid unit include hydroxyl acids other than lactic acid and amino acids (including hydrophobic amino acids and other amino acids).
  • the hydroxyl acid include glycolic acid and hydroxyisobutyric acid.
  • the amino acid may be a natural amino acid or an unnatural amino acid.
  • the amino acid may be an ⁇ -amino acid, ⁇ -amino acid, or ⁇ -amino acid, but is preferably an ⁇ -amino acid.
  • the amino acid is preferably a hydrophobic amino acid, for example, and examples thereof include glycine, alanine, valine, leucine, isoleucine, proline, methionine, tyrosine, and tryptophan.
  • the proportion of structural units other than lactic acid units is usually 10 mol% or less, preferably 5 mol% or less, more preferably 2 mol% or less, and still more preferably 1 with respect to all the structural units constituting the hydrophobic block.
  • the mol% or less most preferably 0 mol%.
  • the hydrophobic block is preferably composed only of lactic acid units.
  • all lactic acid units may be continuous or discontinuous, but the molecular design of the amphiphilic block polymer A as a whole does not impair the basic characteristics described above. Preferably there is.
  • the polylactic acid chain (A-PLA) contained in the hydrophobic block is a poly D-lactic acid chain composed of D-lactic acid units, even if it is a poly L-lactic acid chain composed of L-lactic acid units.
  • it may be a poly DL-lactic acid chain composed of both L-lactic acid units and D-lactic acid units.
  • a person skilled in the art can select appropriately according to the purpose.
  • the order of polymerization of L-lactic acid units and D-lactic acid units is not particularly limited.
  • One or two L-lactic acid units and two D-lactic acid units may be alternately polymerized, may be polymerized randomly, or may be block polymerized.
  • the configuration of A-PLA should be changed.
  • the configuration can be opposite to that of R-PLA. That is, when R-PLA is composed of L-lactic acid units, A-PLA is D-lactic acid unit, and when R-PLA is composed of D-lactic acid units, A-PLA Can be L-lactic acid units.
  • the poly L-lactic acid chain composed of L-lactic acid units is usually 90 mol% or more, preferably 95 mol% or more, more preferably 98 mol, based on the total lactic acid units constituting A-PLA. % Or more, particularly preferably 100 mol% means L-lactic acid units.
  • the poly-D-lactic acid chain composed of D-lactic acid units is usually 90 mol% or more, preferably 95 mol% or more, more preferably 98 mol% or more, based on the total lactic acid units constituting A-PLA. Particularly preferably 100 mol% means D-lactic acid units.
  • amphiphilic block polymer A preferably has no drug or the like in the molecule, but may have a drug or the like as long as the effects of the present invention are not impaired.
  • medical agent etc. are not specifically limited, For example, the photosensitizer mentioned later is mentioned.
  • RNA modified with a compound having a long-chain hydrophobic group If the said compound has a long-chain hydrophobic group, it may have a long-chain hydrophilic group etc. in addition to that.
  • the long-chain hydrophobic group include linear hydrocarbons having 10 to 16 carbon atoms (preferably 12 carbon atoms) with a disulfide bond interposed therebetween, such as polylactic acid chain (R-PLA) and dihexyl disulfide.
  • Preferred examples include groups having a linear saturated hydrocarbon) (eg, dimethoxytrityloxy-hexyldithiohexyl (DMT-C6-SS-C6 group)), and those having a long-chain hydrophilic group as well.
  • examples thereof include polylactic acid / polysarcosine copolymer chains (R-PLA-Sar).
  • Long-chain hydrophobic groups such as polylactic acid chains and DMT-C6-SS-C6 groups are hydrophobic and are usually located in the hydrophobic core of the molecular assembly, and long-chain hydrophilic groups such as polysarcosine chains and RNA Indicates hydrophilicity and is located in the hydrophilic shell.
  • the modified RNA is stably included in the molecular assembly of the present invention.
  • the modified RNA is also included in the present invention.
  • RNA is not particularly limited as long as it has a function such as a gene expression suppressing effect, but a functional RNA capable of acting on and inhibiting the function of mRNA in the cytoplasm is preferable.
  • RNA include siRNA (small interfering RNA), shRNA (short hairpin RNA), miRNA (microRNA), antisense RNA, aptamer RNA, and ribozyme. These can be used alone or in combination of two or more.
  • siRNA a siRNA that knocks down the ATP-binding cassette transporter G2 (ABCG2) gene and suppresses its expression, specifically, for example, a sense strand represented by SEQ ID NO: 10 and SEQ ID NO: 11
  • a double-stranded nucleic acid consisting of an antisense strand (ABCG2 siRNA), an siRNA that knocks down the ferrochelatase gene and inhibits its activity, specifically, for example, a sense strand represented by SEQ ID NO: 12 and SEQ ID NO: 13
  • the double-stranded nucleic acid (Ferrochelate siRNA) which consists of an antisense strand represented can be mentioned.
  • PpIX protoporphyrin IX
  • ALA 5-aminolevulinic acid
  • ALA 5-aminolevulinic acid
  • CDG2 is a transporter that actively discharges PpIX to the outside of the cell
  • ferrochelatase is an enzyme that suppresses intracellular PpIX because it inserts divalent iron into PpIX and converts it into heme.
  • siRNA that suppresses and inhibits the expression or activity of ABCG2 and ferrochelatase can effectively prevent the decrease of PpIX accumulated in cancer cells, so that cancer treatment by photodynamic therapy (PDT) using ALA is possible.
  • PDT photodynamic therapy
  • the siRNA that knocks down the ABCG2 gene and suppresses its expression, and the siRNA that knocks down the ferrochelatase gene and inhibits its activity can be used in any ratio (eg, 1: 1). It is preferable to use together.
  • RNA is usually bound to a polylactic acid chain (R-PLA) or a polylactic acid / polysarcosine copolymer chain (R-PLA-Sar).
  • R-PLA polylactic acid chain
  • R-PLA-Sar polylactic acid / polysarcosine copolymer chain
  • RNA may be bound to the terminal constituent unit of R-PLA or R-PLA-Sar, and may be bound to a constituent unit other than the terminal, but is preferably bound to the terminal constituent unit.
  • R-PLA-Sar it is preferably bound to the end of the sarcosine constituent unit.
  • RNA and R-PLA or R-PLA-Sar may be directly bonded via a reactive group such as a maleimide group, but are generally bonded via a suitable linker in addition to the reactive group.
  • linker examples include polyethylene glycol, polypeptide, aliphatic polyester, and polysaccharide.
  • polypeptide include polyglycine and poly ⁇ -alanine
  • aliphatic polyester include polycaprolactone and polyglycolic acid.
  • the RNA binding site is not particularly limited, but the 3 'end or 5' end is appropriate. Of these, the 3 'end is preferred.
  • double-stranded RNA such as siRNA
  • R-PLA-Sar it is more preferable that the 3 'end of the sense strand and the end of the sarcosine building block of R-PLA-Sar are bound.
  • RNA according to the present invention is modified with a compound having a long-chain hydrophobic group.
  • specific examples of such compounds include polymers having polylactic acid chains (R-PLA) or polylactic acid / polysarcosine copolymer chains (R-PLA-Sar), and dimethoxytrityloxy-hexyldithiohexane. be able to.
  • the polylactic acid chain of the polylactic acid chain (R-PLA) or the polylactic acid / polysarcosine copolymer chain (R-PLA-Sar) is a poly L-lactic acid chain composed of L-lactic acid units.
  • it may be a poly D-lactic acid chain composed of D-lactic acid units or a poly DL-lactic acid chain composed of both L-lactic acid units and D-lactic acid units.
  • a person skilled in the art can select appropriately according to the purpose.
  • the order of polymerization of L-lactic acid units and D-lactic acid units is not particularly limited.
  • One or two L-lactic acid units and two D-lactic acid units may be alternately polymerized, may be polymerized randomly, or may be block polymerized.
  • the configuration of the polylactic acid chain of R-PLA or R-PLA-Sar is changed to the amphiphilic block.
  • the configuration can be opposite to that of the polylactic acid chain (A-PLA) of polymer A. That is, when A-PLA is composed of L-lactic acid units, the polylactic acid chain of R-PLA or R-PLA-Sar is D-lactic acid units, and A-PLA is composed of D-lactic acid units.
  • the polylactic acid chain of R-PLA or R-PLA-Sar can be L-lactic acid units.
  • the poly-D-lactic acid chain composed of D-lactic acid units is usually 90 mol% or more, preferably based on the total lactic acid units constituting the polylactic acid chain of R-PLA or R-PLA-Sar. Means 95 mol% or more, more preferably 98 mol% or more, and particularly preferably 100 mol% is a D-lactic acid unit.
  • the poly-L-lactic acid chain composed of L-lactic acid units is usually 90 mol% or more, preferably based on the total lactic acid units constituting the polylactic acid chain of R-PLA or R-PLA-Sar, preferably It means that 95 mol% or more, more preferably 98 mol% or more, particularly preferably 100 mol% is L-lactic acid units.
  • the number of lactic acid units in the polylactic acid chain of the polylactic acid chain (R-PLA) for modifying RNA and the polylactic acid / polysarcosine copolymer chain (R-PLA-Sar) is usually 10 to 60, preferably 25 to 45. The number is about 25, more preferably about 25 to 35.
  • the number of lactic acid units constituting the polylactic acid chain in the modified RNA should be about 0.8 to 1.2 times the number of lactic acid units constituting the hydrophobic block in the amphiphilic block polymer A. It is preferably about 0.9 to 1.1 times, more preferably about 0.95 to 1.04 times.
  • the number of sarcosine units in the polysarcosine chain of the polylactic acid / polysarcosine copolymer chain (R-PLA-Sar) that modifies RNA is usually 0 to 100 (in the case of 0, it consists only of lactic acid units), preferably 20 to About 80, more preferably about 40-60.
  • the number of sarcosine units constituting the polysarcosine chain in the modified RNA is the number of sarcosine units constituting the hydrophilic block in the amphiphilic block polymer A (however, in the case of the three-branched amphiphilic block polymer A, Is preferably about 0 to 1.0 times, more preferably about 0.2 to 0.8 times, and about 0.4 to 0.6 times. More preferably.
  • the molecule it is preferable to design the molecule so that the total length of the polylactic acid chain (R-PLA) that modifies RNA does not exceed the length of the hydrophobic block of the amphiphilic block polymer A described above. Further, it is preferable to design the molecule so that the total length of the polylactic acid / polysarcosine copolymer chain (R-PLA-Sar) does not exceed the length of the above-mentioned amphiphilic block polymer A.
  • the polylactic acid chain (R-PLA) and polylactic acid / polysarcosine copolymer chain (R-PLA-Sar) that modify RNA may have one or more constituent units other than the lactic acid unit and the sarcosine unit. Good. Examples of such structural units include hydroxyl acids other than lactic acid and amino acids. Examples of the hydroxyl acid include glycolic acid and hydroxyisobutyric acid.
  • the amino acid may be a natural amino acid or an unnatural amino acid.
  • the amino acid may be an ⁇ -amino acid, ⁇ -amino acid, or ⁇ -amino acid, but is preferably an ⁇ -amino acid.
  • the proportion of structural units other than lactic acid / sarcosine units is usually 10 mol% or less, preferably 5 mol% or less, more preferably 2 mol% or less, and still more preferably 1 with respect to all the structural units constituting the polymer.
  • the mol% or less most preferably 0 mol%.
  • the lactic acid unit or the lactic acid unit and the sarcosine unit are preferred.
  • all lactic acid units or sarcosine units may be continuous or discontinuous, but it is preferable that both are continuous.
  • the method for synthesizing a compound having a long-chain hydrophobic group that modifies RNA is not particularly limited. It can be synthesized by a conventional method from a commercially available reagent.
  • polylactic acid and polylactic acid / polysarcosine copolymer can be synthesized according to the synthesis method for the amphiphilic block polymer A. Specifically, the following manufacturing method can be mentioned, for example.
  • the polysarcosine chain of the polylactic acid / polysarcosine copolymer chain can be synthesized by a known peptide synthesis method. For example, it can be carried out by polymerizing a monomer capable of forming a sarcosine unit (hereinafter also referred to as sarcosine monomer) using a base such as an amine as an initiator.
  • a monomer capable of forming a sarcosine unit hereinafter also referred to as sarcosine monomer
  • examples of the sarcosine monomer include sarcosine and N-carboxysarcosine anhydride (sarcosine-NCA), preferably N-carboxysarcosine anhydride. It is preferably carried out by ring-opening polymerization of N-carboxysarcosine anhydride using a base such as amine as an initiator.
  • the synthesis of the polylactic acid chain and the polylactic acid chain of the polylactic acid / polysarcosine copolymer chain can be performed, for example, by a known polyester synthesis method.
  • it can be carried out by polymerizing a monomer capable of forming a lactic acid unit (hereinafter also referred to as lactic acid monomer) using a base such as an amine as an initiator.
  • a monomer capable of forming a lactic acid unit hereinafter also referred to as lactic acid monomer
  • a base such as an amine as an initiator
  • examples of the lactic acid monomer include lactic acid and lactide, and lactide is preferable. It is preferably carried out by ring-opening polymerization of lactide using a base such as amine as an initiator.
  • the lactide can be appropriately determined by those skilled in the art in consideration of the desired stereochemistry (optical purity) of the polylactic acid chain.
  • L-lactide or D-lactide is appropriately selected, and a person skilled in the art can appropriately determine the amount to be used according to the desired stereochemistry (optical purity) of the polylactic acid chain.
  • the chain length of the polysarcosine chain and the polylactic acid chain can be adjusted by adjusting the charge ratio of the initiator and each monomer in the polymerization reaction.
  • the chain length can be confirmed by, for example, 1 H NMR.
  • the synthesis of the polylactic acid / polysarcosine copolymer chain is, for example, by synthesizing a linker reagent that links the polysarcosine chain and the polylactic acid chain, and using it as an initiator, by adding a sarcosine unit or by a polymerization reaction of a sarcosine monomer. This can be achieved by extending the polysarcosine chain and extending the polylactic acid chain by a polymerization reaction of a lactic acid monomer.
  • lactic acid is added to the linker reagent to which the sarcosine or polysarcosine chain is added.
  • a polylactic acid / polysarcosine copolymer chain can be synthesized by polymerizing a monomer to extend a polylactic acid chain.
  • a polysarcosine chain or both a polysarcosine chain and a polylactic acid chain are prepared in advance, and these blocks are linked using a separately synthesized linker reagent, thereby producing a polylactic acid- Polysarcosine copolymer chains can be synthesized.
  • the linker reagent has one functional group (for example, a hydroxyl group, an amino group, etc.) that can be bonded to a lactic acid monomer or a polylactic acid chain, and a functional group that can be bonded to a sarcosine monomer or polysarcosine (for example, , An amino group) is not particularly limited.
  • the functional group capable of binding to the lactic acid monomer or polylactic acid chain and the functional group capable of binding to the sarcosine monomer or polysarcosine may be protected by a protecting group, if necessary.
  • a protecting group those capable of being selectively removed as necessary are appropriately selected by those skilled in the art.
  • the modified RNA can have, for example, a photosensitizer described later in the molecule thereof as long as the effects of the present invention are not impaired.
  • a photosensitizer may be bound on RNA or on a compound that modifies RNA.
  • the content of the modified RNA in the molecular assembly of the present invention varies depending on the type of RNA used, the amphiphilic block polymer A, the RNA modifying compound, the cell membrane binding compound, the type and amount of the photosensitizer, and the like.
  • the amphiphilic block polymer A 100 mol%, it is usually in the range of 1 to 20 mol%, preferably 3 to 15 mol%, more preferably 5 to 10 Mol%.
  • the method for preparing (manufacturing) the modified RNA that is, the method for modifying a compound having a long hydrophobic group in RNA is not particularly limited. Depending on the type of RNA and the like, it can be appropriately prepared by conventional methods.
  • modified RNA when preparing the modified RNA by binding the end of RNA and the end of polylactic acid or polylactic acid / polysarcosine copolymer, a thiol group is introduced into the end of RNA, while polylactic acid or polylactic acid / polylactic acid is prepared.
  • the modified RNA can be prepared by introducing a maleimide group at the end of the sarcosine copolymer and adding the thiol group to the maleimide group.
  • siRNA can be prepared as follows.
  • the sense strand 3 'end of the siRNA is reacted with a thiol compound to synthesize a sense RNA in which the nucleobase at the 3' end is thiolated.
  • Such sense RNA and complementary antisense RNA are annealed by a conventional method to prepare siRNA having a thiol group at the 3 'end of the sense strand.
  • polylactic acid or polylactic acid / polysarcosine copolymer and a maleimide reagent are reacted to prepare polylactic acid or polylactic acid / polysarcosine copolymer having a maleimide group at the terminal.
  • the modified RNA is obtained by addition reaction of the thus obtained siRNA having a thiol group at the 3 ′ end of the sense strand and polylactic acid or polylactic acid / polysarcosine copolymer having a maleimide group at the end by a conventional method. Can be prepared.
  • the thiol compound is not particularly limited as long as it can introduce a thiol group at the end of RNA.
  • a nucleotide having a thiol group in a nucleobase, a nucleotide having an amino group in a nucleobase, or a nucleobase examples include nucleotides having a carboxyl group, and specific examples include nucleotides including 6-thioguanosine, 6-aminoguanosine, 6-carboxyl guanosine, and the like.
  • the maleimide reagent is not particularly limited as long as it can introduce a maleimide group into the terminal of polylactic acid or polylactic acid / polysarcosine copolymer.
  • GMBS N- (4-maleimidobutyryloxy) succinimide
  • GMBS N -(4-maleimidobutyryloxy) sulfosuccinimide
  • EMCS N- (6-maleimidocaproyloxy) sulfosuccinimide
  • GMBS sodium-EMCS.
  • the solvent, reaction temperature, reaction time, and the like can be appropriately set according to the type of RNA, the type of various reagents, and the like.
  • the modified RNA other than siRNA can also be synthesized according to the method for synthesizing the modified siRNA.
  • the molecular assembly of the present invention comprises a cell membrane-binding compound.
  • the molecular assembly of the present invention is in the form of particles such as micelles, it is preferable that the cell membrane-binding compound has a chain length that projects even partly outside the particles.
  • the “cell membrane-binding compound” has a function of binding to a cell membrane and, in some cases, incorporating itself into a cell.
  • the cell membrane binding compound is usually a peptide, a sugar chain, or an antibody.
  • a typical example is a cell membrane permeable peptide (CPP).
  • CPP is a peptide rich in basic amino acids (cationic amino acids) such as arginine, is an amphiphilic peptide that is basic and contains hydrophobic amino acids, and is mostly a hydrophobic amino acid with a slight basicity. It may be a peptide containing an amino acid.
  • CPP is generally considered to be taken up into cells mainly via the cell endocytosis pathway. Sometimes referred to as a membrane permeability domain (PTD).
  • PTD membrane permeability domain
  • the compound is not particularly limited as long as it has a function capable of binding to a cell membrane, but CPP is preferable.
  • CPP is not particularly limited. It may have a wild-type amino acid sequence, or may have a mutant amino acid sequence in which substitution, deletion, or addition has been made to the wild-type amino acid sequence as long as it has the ability to enter cells It may be a thing.
  • Amphiphilic CPP or hydrophobic CPP is preferred. This is because these easily form a molecular assembly together with the amphiphilic block polymer A.
  • CPP include an MPG peptide having the amino acid sequence shown in SEQ ID NO: 1 contained in the fusion protein gp41 derived from human immunodeficiency virus type I (HIV-1), and a trans-activator derived from HIV-1.
  • a polypeptide represented by SEQ ID NO: 2 a polypeptide represented by SEQ ID NO: 3 derived from a flockhouse virus (FHV), a CTP512 having an amino acid sequence represented by SEQ ID NO: 4 (included in of transcription protein (Tat protein)) Cytoplasmic Transduction Peptide), Pep peptide having the amino acid sequence shown by SEQ ID NO: 5, DPV3 peptide having the amino acid sequence shown by SEQ ID NO: 14, and shown by SEQ ID NO: 15 PTD4 peptide having a mino acid sequence, Pep1 peptide having an amino acid sequence represented by SEQ ID NO: 16, EB1 peptide having an amino acid sequence represented by SEQ ID NO: 17, Rev peptide, feline herpesvirus Coat protein-derived peptide, polyarginine, CADY peptide Can be mentioned.
  • the MPG peptide having the amino acid sequence represented by SEQ ID NO: 1 is preferred. These can be used alone or in combination of two or more.
  • SEQ ID NO: 1 GALFLGFLGAAGSTMGAWSQPKKRKRKV
  • SEQ ID NO: 2 YGRKKRRQRRRG
  • SEQ ID NO: 3 RRRRNRTRRNRRRVR
  • SEQ ID NO: 4 YGRRRRRRRRR Sequence number 5: KETWWETWWTE
  • SEQ ID NO: 14 RKKRRRESRKKRRRESC
  • SEQ ID NO: 15 YARAAARQARAC Sequence number 16: KETWWETWWTEWSQPKKRKRKVC
  • SEQ ID NO: 17 LIRLWSHLIHIWFQNRRLKWKKKKC
  • the MPG peptide is an amphipathic peptide, but even if it is a Pep peptide or the like that is not an amphipathic peptide, for example, by having a hydrophobic sequence via a WSQ amino acid sequence (linker), the MPG peptide should be an amphipathic peptide. Can do.
  • the content of cell membrane-binding compound in the molecular assembly of the present invention depends on the type of cell membrane-binding compound used, amphiphilic block polymer A, modified RNA, photosensitization. Depending on the type and amount of the agent, it may be appropriately selected. For example, based on the amphiphilic block polymer A (100 mol%), it is usually in the range of 1 to 50 mol%, preferably 5 to 25 The mol%, more preferably 10 to 20 mol%.
  • the cell membrane-binding compound according to the present invention can have a photosensitizer described later in the molecule, and preferably has a photosensitizer as long as the effects of the present invention are not impaired.
  • Photosensitizer The molecular assembly of the present invention contains a photosensitizer.
  • Photosensitizer The “photosensitizer” according to the present invention is incorporated into cells and localized in endosomes by, for example, irradiation with light (near infrared light or light having a wavelength close thereto). It has a function capable of diffusing the accumulated molecular assembly into the cytoplasm. This diffusion mechanism is presumed to be because the photosensitizer excited by light irradiation generates singlet oxygen, which destabilizes (destroys) the endosomal membrane.
  • Examples of the wavelength of the excitation light include a wavelength region of 450 to 1300 nm.
  • the near infrared light wavelength region is preferably 500 to 1200 nm, more preferably 700 to 1000 nm.
  • Photosensitizers having maximum excitation wavelengths in these regions can be used.
  • near-infrared light avoids absorption by hemoglobin or water in the living body, and has a characteristic that it easily transmits through living tissue.
  • the photosensitizer according to the present invention is not particularly limited as long as it has the above function and has a maximum excitation wavelength in the above wavelength region.
  • Various photosensitizers are known and are commercially available, and appropriate commercial products can be used. Examples thereof include cyanine dyes such as fluorescein dyes and indocyanine dyes, rhodamine dyes, porphyrin dyes, and quantum dots.
  • DY750 (manufactured by DYOMICICS GmbH), DY751 (manufactured by DYOMICICS GmbH), DY780 (manufactured by DYOMICICS GmbH), Alexa Fluor (registered trademark) 633 (manufactured by Invitrogen), Alexa Fluor (registered trademark) 750 (manufactured by Invitrogen), Alexa Fluor (registered trademark) 546 (manufactured by Invitrogen), IRDye (registered trademark) 800CW (manufactured by LI-COR), Eosin, Rosebengal, Indocyanine Green (ICG) ), Etc., Cy (registered trademark) 7, DY776, Alexa FLuor (registered trademark) 790, carboxyfluorescein (FAM).
  • DY750, Alexa Fluor (registered trademark) 546, Alexa Fluor (registered trademark) 633, DY751, DY780 Alexa Fluor (register
  • the photosensitizer according to the present invention can be present alone in the molecular assembly of the present invention, but generally there are many water-soluble photosensitizers. Therefore, in order to be effectively included in the molecular assembly, as described above, it is preferably present in the molecule of one or more other components constituting the molecular assembly of the present invention. Among them, it is preferable to exist in the molecule of the cell membrane binding compound.
  • the binding between the cell membrane-binding compound and the photosensitizer can be performed by a conventional method.
  • the cell membrane-binding compound is a CPP peptide
  • a unique cysteine in the CPP is placed near the N-terminus or near the C-terminus, while the photosensitizer selectively reacts with the thiol group of the cysteine.
  • a maleimide group (which does not react with other amino acid residues of CPP) has been introduced, and the reaction can be carried out via a bond reaction between these thiols and maleimides.
  • the maleimide reagent for introducing a maleimide group include the same maleimide reagents used for the preparation of modified RNA.
  • CPP can be similarly bonded to CPP using a commercially available “photosensitizer with a maleimide group”.
  • a photosensitizer with a maleimide group For example, after mixing a photosensitizer with a maleimide group and a CPP containing cysteine at one end, the unreacted photosensitizer is removed using a gel filtration spin column, etc.
  • the agent and CPP can be combined.
  • the content of the photosensitizer in the molecular assembly of the present invention depends on the type of photosensitizer used, the amphiphilic block polymer A, the modified RNA, and the cell membrane-binding compound. Depending on the type and amount, the presence or absence of binding with other components, etc., it may be selected as appropriate. , Preferably 1 to 10 mol%, more preferably 1 to 5 mol%.
  • the molecular assembly of the present invention is a structure constituted by aggregation of the amphiphilic block polymer A or by self-assembled orientation.
  • a micelle-shaped molecular assembly polylactic acid-based amphiphilic polymer micelle configured such that the inner side (core portion) is a hydrophobic block and the outer side (shell portion) is a hydrophilic block is used.
  • a micelle-shaped molecular assembly in which a part of the cell membrane-binding compound protrudes outward is preferable.
  • the particle size of the molecular assembly of the present invention can be appropriately adjusted depending on the type and ratio of the amphiphilic block polymer A, the modified RNA, the cell membrane-binding compound, and the photosensitizer used.
  • the thickness may be 10 to 100 nm.
  • the thickness is preferably 10 to 50 nm, more preferably 10 to 30 nm.
  • the “particle diameter” means a particle diameter having the highest frequency of appearance in the particle distribution, that is, a central particle diameter.
  • the particle diameter of the molecular assembly is preferably 30 nm or less, more preferably less than 30 nm.
  • the method for measuring the size of the molecular assembly of the present invention is not particularly limited, and can be appropriately selected by those skilled in the art. For example, it can be measured by an observation method using a transmission electron microscope (TEM), an atomic force microscope (AFM), a dynamic light scattering (DLS) method, or the like.
  • TEM transmission electron microscope
  • AFM atomic force microscope
  • DLS dynamic light scattering
  • the production method of the molecular assembly of the present invention is not particularly limited, depending on the size, characteristics, type of functional structure to be supported, nature, content, etc. Those skilled in the art can select as appropriate. If necessary, after the molecular assembly is formed as described below, the obtained molecular assembly may be subjected to surface modification by a known method. In addition, confirmation that the particles are formed can be usually performed by observation with an electron microscope.
  • the amphiphilic block polymer A in the present invention has solubility in a low boiling point solvent, for example, the molecular assembly of the present invention can be prepared by using a so-called film method.
  • the film method includes, for example, the following steps.
  • a step of preparing a solution containing a molecular assembly component such as amphiphilic block polymer A or modified RNA in an organic solvent in a container that may contain glass beads (hereinafter also referred to as “step (a1)”). ), Removing the organic solvent from the solution to obtain a film containing the amphiphilic block polymer A or the like on the inner wall of the container (hereinafter, also referred to as “step (a2)”), and water or an aqueous solution in the container And applying ultrasonic treatment or heating treatment to convert the film into a molecular assembly to obtain a molecular assembly dispersion (hereinafter also referred to as “step (a3)”).
  • Step (a1) to step (a3) are usually performed in this order.
  • the preparation method including the above steps (a1) to (a3) is suitably used as the method for preparing the molecular assembly of the present invention.
  • the film method may include a step of subjecting the molecular assembly dispersion to a freeze-drying treatment.
  • the container used at a process (a1) is not specifically limited, For example, a glass container etc. can be used.
  • the shape of the container is not particularly limited.
  • the method for preparing the solution containing the amphiphilic block polymer A or the like in the organic solvent is not particularly limited, and the solution may be prepared by mixing the amphiphilic block polymer A or the like in the organic solvent. May be stocked in the state of a film in advance, and when preparing a molecular assembly, it may be prepared by adding a solution containing other constituents and dissolving the film.
  • the concentration of the amphiphilic block polymer A in the organic solvent varies depending on the type and the type of other components, but is preferably 10% (w / v) or less, for example, 1% (w / v) More preferably, it is as follows.
  • the lower limit of the concentration is preferably 0.1% (w / v).
  • the concentration of the modified RNA according to the present invention in the organic solvent is, for example, preferably 5% (w / v) or less, and more preferably 2.5% (w / v) or less.
  • the lower limit of the concentration is preferably 0.1% (w / v).
  • the concentration is preferably 10 mol% or less, more preferably 5 mol% or less, further preferably 2 mol% or less, particularly preferably 1 mol% or less, based on the amphiphilic block polymer A. It is preferable to do.
  • the concentration of the cell membrane-bound compound or the cell membrane-bound compound to which the photosensitizer is bound in the organic solvent is, for example, preferably 1% (w / v) or less, and 0.5% (w / v) or less. More preferably.
  • the lower limit of the concentration is preferably 0.01% (w / v), for example.
  • the concentration is preferably 1 mol% or less, more preferably 0.5 mol% or less, still more preferably 0.2 mol% or less, particularly preferably 0.1 mol, based on the amphiphilic block polymer A. % Or less is preferable.
  • the concentration of the photosensitizer in the organic solvent is, for example, preferably 1% (w / v) or less, and more preferably 0.5% (w / v) or less.
  • the lower limit of the concentration is preferably 0.1% (w / v).
  • the concentration is preferably 1 mol% or less, more preferably 0.5 mol% or less, still more preferably 0.2 mol% or less, particularly preferably 0.1 mol, based on the amphiphilic block polymer A. % Or less is preferable.
  • the organic solvent used in the film method it is preferable to use the above-described low boiling point solvents.
  • specific examples include chloroform, diethyl ether, acetonitrile, methanol, ethanol, acetone, dichloromethane, tetrahydrofuran, hexane and the like.
  • the method for removing the solvent in the step (a2) is not particularly limited, and may be appropriately determined by those skilled in the art according to the boiling point of the organic solvent to be used. For example, it can be removed by solvent removal under reduced pressure, solvent removal by natural drying, or the like.
  • a film containing amphiphilic block polymer A or the like is formed on the inner wall of the container.
  • water or an aqueous solution is added to the container to which the film is attached. It does not specifically limit as water or aqueous solution, For example, it can select suitably according to the use of a molecular assembly. Those skilled in the art may appropriately select biochemically or pharmaceutically acceptable ones. Examples of such water or aqueous solution include distilled water for injection, physiological saline, and buffer solution. The amount of water or aqueous solution added is, for example, usually 10 to 1000, preferably 10 to 100 in terms of mass ratio with respect to the amphiphilic block polymer A used in step (a1).
  • ultrasonic treatment or heating treatment is performed.
  • a molecular assembly is formed in the process of peeling the film from the inner wall of the container by ultrasonic waves or heating.
  • the heating treatment can be performed, for example, under conditions of 70 ° C. to 100 ° C. and 5 minutes to 60 minutes.
  • the ultrasonic treatment is preferably performed, for example, at room temperature to 100 ° C. for about 2 to 60 minutes.
  • a dispersion in which the molecular assembly is dispersed in the water or aqueous solution is prepared in a container.
  • ultrasonic treatment and heating treatment may be performed together.
  • the molecular assembly of the present invention can also be prepared by a so-called injection method.
  • the injection method preferably includes the following steps.
  • a step of preparing a solution containing molecular assembly components such as amphiphilic block polymer A and modified RNA in an organic solvent hereinafter also referred to as “step (b1)”
  • a step of dispersing the solution in water or an aqueous solution hereinafter also referred to as “step (b2)”
  • step (b3) a step of removing the organic solvent
  • the preparation method including the above steps (b1) to (b3) is preferably used as a method for preparing the molecular assembly of the present invention.
  • a molecular assembly prepared by a preparation method including the above steps is one of the preferred embodiments of the present invention.
  • a purification treatment step may be appropriately performed before the step of removing the organic solvent.
  • the container used for the injection method is not particularly limited, and for example, a test tube or the like can be used.
  • the organic solvent used in the step (b1) include trifluoroside and dimethylformamide.
  • a method for preparing a solution containing the amphiphilic block polymer A or the like in an organic solvent is not particularly limited, and a method similar to the method for preparing a solution in the film method described above can be employed.
  • the water or aqueous solution in the step (b2) is not particularly limited, and examples thereof include purified water, distilled water for injection, physiological saline, and buffer solution.
  • Water or an aqueous solution is usually used 5 to 100 times (volume ratio) with respect to a solution containing the amphiphilic block polymer A or the like in an organic solvent.
  • a method for dispersing a solution containing the amphiphilic block polymer A or the like in an organic solvent in water or an aqueous solution is not particularly limited, and can be performed by, for example, a mixer.
  • the organic solvent is removed from water or an aqueous solution in which the organic solvent containing the amphiphilic block polymer A or the like is dispersed.
  • the method for removing the organic solvent in the step (b3) is not particularly limited, and can be performed by the method described above. Examples of the purification treatment include gel filtration chromatography, filtering, ultracentrifugation and the like. A combination of these can also be performed.
  • a dispersion of molecular aggregates obtained by a film method, an injection method, or the like can be directly administered to a living body. Moreover, it can also preserve
  • the method of lyophilization treatment is not particularly limited, and can be performed by a known method.
  • the molecular assembly dispersion obtained as described above can be frozen by liquid nitrogen or the like and sublimated under reduced pressure. Thereby, a freeze-dried product of the molecular assembly is obtained. That is, the molecular assembly can be stored as a lyophilized product.
  • the molecular aggregate can be used for use by adding water or an aqueous solution to the lyophilized product to obtain a dispersion of the molecular aggregate. It does not specifically limit as water or aqueous solution, For example, it can select suitably according to the use of a molecular assembly. Those skilled in the art may appropriately select biochemically or pharmaceutically acceptable ones. Examples of such water or aqueous solution include distilled water for injection, physiological saline, and buffer solution.
  • RNA delivery system into tumor cytoplasm The present invention also includes an RNA delivery system into tumor cytoplasm using the molecular assembly of the present invention.
  • RNA delivery system of the present invention usually comprises administering the molecular assembly into an animal (living body).
  • the animal to which the molecular assembly can be administered is not particularly limited, and examples thereof include human or non-human animals.
  • Non-human animals are not particularly limited, but mammals other than humans, specifically, primates, rodents (mouse, rats, etc.), rabbits, dogs, cats, pigs, cows, sheep, horses, etc. Can be mentioned.
  • the molecular assembly is excellent in specific accumulation at a malignant tumor site or the like. Since the molecular assembly of the present invention accumulates in the tissue of the malignant tumor site due to the EPR (Enhanced Permeability and Retention) effect, the accumulation does not depend on the tissue type of the malignant tumor site.
  • an administration target of the molecular assembly of the present invention an animal having a malignant tumor site or an animal having a possibility of having a malignant tumor site is preferable.
  • the tumor that can be a target for administering the molecular assembly of the present invention is not particularly limited, and examples thereof include solid cancers such as liver cancer, pancreatic cancer, lung cancer, cervical cancer, breast cancer, and colon cancer.
  • the method of administration to animals is not particularly limited and can be appropriately determined by those skilled in the art.
  • the administration method may be systemic administration or local administration.
  • the molecular assembly can be administered by any of injection (needle-type, needle-free), internal use, and external use. It is preferable to select an effective route for prevention or treatment.
  • parenteral administration such as intravenous injection, subcutaneous injection, intramuscular injection, etc. in addition to oral administration.
  • parenteral administration such as intravenous injection, subcutaneous injection, intramuscular injection, etc. in addition to oral administration.
  • local administration for example, it is administered to the skin, mucous membrane, lung, bronchi, nasal cavity, nasal mucosa, eye and the like.
  • it is administered parenterally, more preferably by intravenous injection.
  • the dose of the molecular assembly of the present invention is not particularly limited, and can be appropriately selected according to the type of RNA, the target site, etc. of the molecular assembly.
  • the molecular assembly After administration of the molecular assembly of the present invention in vivo, the molecular assembly is included in the molecular assembly at an appropriate time when it reaches the target site (tumor affected area).
  • the modified RNA can be diffused and delivered into the tumor cytoplasm by irradiating the affected tissue with light having a wavelength that is excited by the photosensitizer being used for an appropriate time for an appropriate energy.
  • the modified RNA acts on mRNA and the like, its function (gene expression suppression function) is exhibited, and tumor cells in the affected tissue can be killed.
  • RNA of the modified RNA is siRNA that knocks down the ABCG2 gene and suppresses its expression, siRNA that knocks down the ferrochelatase gene and inhibits its activity, or a combination of both, photodynamics using ALA
  • ALA-PDT clinical therapy
  • the reduction of PpIX accumulated in cancer cells is prevented by the action of the siRNA, and the reactive oxygen species generated by light irradiation to PpIX can effectively kill the tumor cells. .
  • the transfer of the modified RNA into the cytoplasm is thought to be due to the following mechanism.
  • the molecular assembly administered into the living body is taken into the endosome by endocytosis, and the photosensitizer in the molecular assembly exerts its function by light stimulation.
  • the endosomal membrane and the molecular assembly (micelle structure) It is considered that the modified RNA or the like is destroyed and moves into the cytoplasm (see FIG. 1).
  • the light irradiation time varies depending on the type and content of the photosensitizer, the wavelength, the type and state of the tumor, the position, etc., but is usually 1 to 600 seconds.
  • the time is preferably 1 second to 100 seconds, more preferably 1 second to 60 seconds. It is sufficient that energy of 1 to 300 J / cm 2 is usually given to the affected area within these times.
  • Cancer preventive agent / therapeutic agent, cancer preventive / therapeutic system, cancer preventive method / therapeutic method has functional RNA and effectively migrates into the cytoplasm of tumor tissue, It is useful as a medicine (micelle preparation) used for the prevention or treatment of cancer.
  • the prophylactic or therapeutic agent of the present invention may be a pharmaceutical composition containing a carrier or the like usually used in the pharmaceutical field as long as the effects of the present invention are not impaired.
  • a pharmaceutical composition can be produced by, for example, a known preparation method by mixing a molecular assembly and a carrier.
  • the dosage form of the pharmaceutical composition is not particularly limited, and preparations for parenteral administration include, for example, injections, ointments, gels, creams, patches, liniments, suppositories, sprays, inhalants, sprays Agents, eye drops, and nasal drops.
  • preparation for oral administration include powders, granules, tablets, capsules, syrups, and liquids.
  • it is a formulation for parenteral administration, and among them, an injection is preferable.
  • the dispersion of the molecular assembly described above can be used as an injection as it is.
  • the present invention also includes a preventive or therapeutic system for cancer comprising the prophylactic or therapeutic agent and a device comprising means for irradiating light for exciting the photosensitizer in the molecular assembly contained therein.
  • a means for irradiating excitation light for exciting the photosensitizer in the molecular assembly contained in the preventive agent or therapeutic agent of the present invention for example, a light source device for photodynamic therapy (PDT) (for example, Panasonic) Examples thereof include medical semiconductor laser devices (for example, UDL-15 manufactured by Olympus Corporation) such as PDT semiconductor laser manufactured by Healthcare Corporation.
  • PDT photodynamic therapy
  • a dye laser, a pulse wave excimer die laser, a wavelength tunable laser, and a semiconductor laser using a die laser, an excimer laser, or the like as excitation light can be given.
  • a light source device incorporating a halogen lamp, a xenon lamp, a fluorescent lamp, an LED, or the like can also be given.
  • the cancer prevention or treatment system according to the present invention may include, for example, means for analyzing the position of the tumor and means for matching the irradiation position of the light source with the tumor. Specific examples include an infrared observation camera system (PDE-NEO C10935-20 manufactured by Hamamatsu Photonics).
  • the prophylactic or therapeutic agent can be administered in vivo, and after administration, for example, irradiation with excitation light of the administered photosensitizer for an appropriate period of time can prevent or treat cancer.
  • the animals that can be administered, the target cancer (tumor), the light irradiation time, etc. are the same as described above.
  • Prevention or treatment of cancer also includes cancer cell growth inhibition, metastasis inhibition and the like.
  • the present invention includes administering the prophylactic or therapeutic agent in vivo, and irradiating light for exciting the photosensitizer in the molecular assembly contained in the administered prophylactic or therapeutic agent. Also included are methods for preventing or treating cancer.
  • Synthesis Example 1 Synthesis of RNA modified with polylactic acid / polysarcosine copolymer
  • Synthesis of PLLA30-PS56-siRNA (a block copolymer consisting of a polylactic acid having an average chain length of 30 mer and a polysarcosine having an average chain length of 56 mer and an siRNA linked thereto) as a polylactic acid / polysarcosine copolymer modified RNA according to the present invention (See FIG. 2).
  • a polylactic acid / polysarcosine copolymer (PLLA-PS-maleimide) having a maleimide group at the end of the polysarcosine chain side was prepared by the following method. After dissolving 100 mg of NH-PS56-PLLA30 in 2.5 mL of dry dimethylformamide (DMF), 21.3 mg (5 equivalents) of N-succimidyl 3-Maleidopropionate and 5.45 ⁇ L (2 equivalents) of diisopropylenelaminate were added, and the mixture was stirred for 7 hours at room temperature. Stir. After distilling off DMF, the resulting white precipitate was washed three times with ethyl acetate to obtain PLLA30-PS56-maleimide (yield: 59.1 mg).
  • DMF dry dimethylformamide
  • siRNA is an anti-GFP (anti-green fluorescent protein) sequence siRNA (SEQ ID NOs: 6 and 7 below) having a thiol group at the 3 ′ end of the sense strand and a FAM fluorescent dye at the 3 ′ end of the antisense strand.
  • SEQ ID NOs: 6 and 7 anti-green fluorescent protein sequence siRNA
  • the sense strand and the antisense strand were mixed at a concentration of 20 ⁇ M and annealed in an aqueous solution containing 20 mM Tris-HCl and 2 mM Mg (OAc) 2 (at 85 ° C. for 2 minutes). Double-stranded siRNA was formed by slow cooling after heating.
  • Sense strand (SEQ ID NO: 6): 5'-GGCUACGUCCAGGAGCGCadTdT-3 '
  • Antisense strand (SEQ ID NO: 7): 5'-UGCGCUCCUGGACGGUAGCCdTdT-3 '
  • reaction was carried out at 25 ° C. for 3 hours at various mixing ratios (1: 2, 1: 5, 1:10) of various PLLA30-PS56-maleimide to siRNA, and about 0.7 ⁇ L of the reaction product was run. 8% Urea PAGE. The result is shown in FIG.
  • RNA modified with dimethoxytrityloxy-hexyldithiohexane (DMT-C6-SS-C6)]
  • SiRNA (anti-EGFP sequence) sense strand with DMT-C6-SS-C6 group added to the 5 ′ end and siRNA (anti-EGFP sequence) antisense strand were purchased from Nippon Bioservice Co., Ltd.
  • the RNA sequences of the sense strand and antisense strand are the same as SEQ ID NOs: 6 and 7.
  • the structure of the DMT-C6-SS-C6 group is as follows, which is attached to the oxygen atom of the 5 ′ terminal phosphate group of the sense strand.
  • Synthesis was performed by preparing a solution having the composition shown in Table 3 and incubating at 25 ° C. for 2 hours. Then, the solution was purified with an HPLC apparatus (PU970, PU-980, DG-980-50, LG-980-02, 821-FP, manufactured by Jasco). A C18 column was used as the column, acetonitrile and 0.1% trifluoroacetic acid (TFA) aq were used as the solvent, and purification was performed with a gradient of acetonitrile 0 ⁇ 100% in 40 minutes. The purified photosensitizer-modified peptide was then dissolved in MilliQ water after removing the solvent using an evaporator. The obtained product was confirmed to have the same molecular weight by an HPLC-CHIP / QTOF mass spectrometer (G6520, G4240, manufactured by Agilent Technologies).
  • RNA introduction were carried out on wells of a 96-well plate, the medium was removed 20 hours after the introduction, washed with 100 ⁇ L of PBS, and treated with 20 ⁇ L of trypsin. After treatment for 5 minutes, 100 ⁇ L of F12 medium was added, suspended, and transferred to a 1.5 mL tube. After centrifugation at 4 ° C. and 5000 rpm for 5 minutes, the supernatant was removed and resuspended in 250 ⁇ L of PBS. The solution was measured by flow cytometry. The result is shown in FIG.
  • siRNA modified with polylactic acid / polysarcosine copolymer (modified siRNA according to the present invention) certainly has physiological activity.
  • ABCG2 siRNA that knocks down the cassette transporter G2 (ABCG2) gene (double-stranded nucleic acid consisting of SEQ ID NO: 10 and SEQ ID NO: 11), FECH siRNA that knocks down the ferrochelatase (FECH) gene (SEQ ID NO: 12 and SEQ ID NO: 13) A double-stranded nucleic acid) was introduced.
  • ABCG2 siRNA was added to a final concentration of 100 nmol / L
  • FECH siRNA was added to a final concentration of 20 nmol / L.
  • RNA was introduced and cultured on the wells of a 6-well plate, and after 0, 24, and 48 hours from the introduction, the cells were collected and washed with 1 mL of PBS. After centrifuging the cell suspension (4 ° C, 3500 rpm for 5 minutes), the supernatant is removed, and RIPA (Radio-Immunoprecipitation assay) buffer (composition, 50 mmol / Tris-HCl (pH8.0), 150 mmol / L) Cells were lysed with sodium chloride, 0.5% (w / v) sodium deoxycholate, 0.1% (w / v) sodium dodecyl sulfate, 1% (w / v) NP-40. Each sample was added with SDS sample buffer to a concentration of 1 mg / mL and heated at 100 ° C. for 5 minutes. The protein concentration was measured from a standard curve with bovine serum albumin using BCA protein assay kit (Pierce).
  • RIPA Radio-Immunopre
  • Each sample was analyzed by the following procedure by Western blotting. 20 ⁇ g of protein was electrophoresed using a 10% polyacrylamide gel. Proteins present in the gel were transferred to a PVDF membrane using a transfer device.
  • the PVDF membrane is 1 with a TBS-T (150 mmol / L sodium chloride, 0.05% (v / v) Tween 20, 10 mmol / L Tris-HCl, pH 7.4) solution containing 5% (w / v) skim milk. Time blocking was performed.
  • Anti-ABCG2 antibody manufactured by Cell signaling Technology
  • anti-FECH antibody manufactured by Cell signaling Technology
  • anti-actin antibody manufactured by Millipore
  • TBS-T solution 5 minutes, 3 times
  • HRP horse radish peroxidase
  • RNAi effect As shown in FIG. 7, a decrease in the expression level of ABCG2 was observed 48 hours after RNA introduction in both 211H cells and CFPAC1 cells. On the other hand, the expression level of ferrochelatase (FECH) decreased strongly in 24 hours, and a remarkable suppression effect was observed so that it was not detected after 48 hours. This result shows that the siRNA used has indeed an RNAi effect.
  • FECH ferrochelatase
  • RNA was introduced in the same manner as in Test Example 3 (1). 48 hours after RNA introduction, 5-aminolevulinic acid (ALA) was added to the medium to a final concentration of 0.5 mmol / L. After 3 hours of culture, the medium was removed, and the cells were collected using a trypsin solution and washed with 1 mL of PBS. The cell suspension was centrifuged (4 ° C., 3500 rpm for 5 minutes), and then the supernatant was removed and resuspended in 0.5 mL of PBS. The cell suspension was analyzed by flow cytometry. The result is shown in FIG.
  • the amount of intracellular protoporphyrin IX increases as the peak of the histogram shifts to the right.
  • ALA treatment control (+) ALA line
  • PpIX accumulation was observed in the cells into which siRNA was introduced.
  • marked PpIX accumulation was observed in cells into which both ABCG2 siRNA and ferrochelatase siRNA were introduced (ABCG2 + FECH line), and it is clear that these siRNAs are effective for accumulation of intracellular PpIX.
  • RNA was introduced in the same manner as in Test Example 3 (1). 48 hours after RNA introduction, 5-aminolevulinic acid (ALA) was added to the medium to a final concentration of 0.5 mmol / L. Cells were irradiated with light (wavelength: 530 nm to 700 nm centered at 630 nm, output: 29 mW / cm 2 ) for 10 minutes using TheraBeam VR630 (manufactured by Ushio Lighting) equipped with a Na-Li lamp after 3 hours of culture. . Thereafter, the cells were further cultured for 24 hours.
  • ALA 5-aminolevulinic acid
  • the MTT solution was added to the medium to 0.0125 mg / mL, and the culture was continued for 30 minutes. After removing the medium and washing the cells with 1 mL of PBS to remove PBS, 1 mL of dimethyl sulfoxide was added to solubilize the formazan produced in the cells. 100 ⁇ L of the solution was transferred to a 96-well plate, the absorbance (570 nm) was measured with a microplate reader, and the cell viability was calculated. The cell viability of the negative control was 100%. The result is shown in FIG.
  • siRNA used is effective in improving the efficiency of photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA).
  • the obtained particles were nano-sized particles.
  • a part of the cell membrane binding compound protrudes from the outside (shell part) of the micelle.
  • each phase difference image was taken, and each FAM image and Alexa 546 image were taken before irradiating the excitation light.
  • Alexa 546 was irradiated with 530-550 nm excitation light through an x20 objective lens for 11 seconds using an fluorescence microscope Olympus IX51 and left for 2 minutes to photograph a FAM image and an Alexa 546 image.
  • DY750 was irradiated with an LED light L750-66-60 from epitex for 5 minutes, and then a FAM image was taken.
  • the results are shown in FIGS.
  • the modified siRNA is labeled with FAM, and the FAM image shows the localization of the modified siRNA.
  • Alexa546-labeled peptide and modified RNA pierced into the molecular assembly entered each cell after 2 hours of cell treatment, and were mainly localized in vesicles (considered as endosomes) ( (See the photo before light irradiation).
  • Alexa546 also has a function as a photosensitizer, and after irradiating the excitation light for 11 seconds, it escaped from the endosome and diffused into the cytoplasm (see photo after light irradiation).
  • FIG. 12 relating to DY750 it is clear that the modified siRNA spreads in the cytoplasm after light irradiation (see FAM photographic image after light irradiation).
  • this polymer-modified RNA could be easily incorporated into amphiphilic block polymer A formed by a similar polymer and was delivered into the cytoplasm.
  • the molecular assembly of the present invention can deliver RNA into the cytoplasm.
  • a small chloroform solution (100 ⁇ L) of 20 nmoL PLLA30-PS70, 10 pmoL DMT-C6-SS-C6-modified siRNA, 250 pmoL cell membrane-binding compound (two CPP peptides (1: 1), DY750 modified)
  • a test tube (Durham tube) to form a film
  • drying was performed under reduced pressure for 1 hour. Subsequent operations are the same as in Test Example 3 (1).
  • Sequence name DPV3 (SEQ ID NO: 14): RKKRRRESRKKRRRESC Sequence name PTD4 (SEQ ID NO: 15): YARAAARQARAC Sequence name Pep1 (SEQ ID NO: 16): KETWWETWWTEWSQPKKRKRKVC Sequence name EB1 (sequence number 17): LIRLWSHLIHIWFQNRRLKWKKKKC
  • the photosensitizer used in the experiment is obtained by binding PLLA34 composed of 34 polylactic acids to indocyanine green (ICG) (ICG-PLLA34).
  • ICG indocyanine green
  • IVIS For imaging, IVIS was used to irradiate excitation light of 745 nm, and the fluorescence intensity of the ICG image was measured at a wavelength of 840 nm and an exposure time of 10 seconds.
  • the present invention provides an RNA delivery system (DDS) into the tumor cytoplasm and a cancer preventive agent or cancer therapeutic agent. Useful as.
  • DDS RNA delivery system
  • Sequence number 4 CTP512 SEQ ID NO: 5: Pep peptide
  • SEQ ID NO: 6 sense strand of anti-GFP siRNA, 2 nucleotides at the 3 ′ end are composed of DNA, and the other is RNA.
  • SEQ ID NO: 7 antisense strand of anti-GFP siRNA, 2 nucleotides at 3 ′ end are composed of DNA, others are RNA.
  • Sequence number 8 It has cysteine at the N terminal of MPGdNLS.
  • SEQ ID NO: 10 sense strand of ABCG2 siRNA, two nucleotides at the 3 ′ end are composed of DNA, and the other is RNA.
  • SEQ ID NO: 11 Antisense strand of ABCG2 siRNA, 2 nucleotides at 3 ′ end are composed of DNA, and the other is RNA.
  • SEQ ID NO: 12 Sense strand of Ferrochelatase siRNA, 2 nucleotides at 3 ′ end are composed of DNA, others are RNA.
  • SEQ ID NO: 13 antisense strand of Ferrochelatase siRNA, 2 nucleotides at 3 ′ end are composed of DNA, other is RNA.
  • Sequence number 14 DPV3 SEQ ID NO: 15: PTD4 SEQ ID NO: 16: Pep1 SEQ ID NO: 17: EB1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention aborde principalement le problème de la fourniture d'un nouvel assemblage moléculaire contenant de l'ARN fonctionnel, apte à introduire dans une cellule des ARN fonctionnels, tels que de l'ARNsi et de l'ARNsh, par une administration in vivo, et également apte à administrer des ARN fonctionnels au niveau d'un site pathologique. La présente invention concerne, par exemple, un assemblage moléculaire caractérisé par le fait qu'il contient comme composants essentiels les éléments suivants : un bloc polymère amphiphile A possédant un bloc hydrophile comprenant une chaîne sarcosine et un bloc hydrophobe comprenant une chaîne d'acide lactique ; de l'ARN modifié par un composé possédant un groupe hydrophobe à chaîne longue tel qu'une chaîne d'acide polylactique ou une chaîne de copolymère acide polylactique-polysarcosine ; un composé de liaison à la membrane plasmatique (CPP, etc.) ; et un photosensibilisateur qui peut se lier à un ou plusieurs de ces composants. La présente invention est utilisable en tant que système d'administration d'ARN (DDS) dans le cytoplasme de cellules tumorales et en tant qu'agent de prévention ou de traitement contre le cancer.
PCT/JP2015/081352 2014-11-08 2015-11-06 Assemblage moléculaire contenant de l'arn modifié, et système d'administration de l'arn à l'aide de ce dernier Ceased WO2016072500A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016557827A JP6586103B2 (ja) 2014-11-08 2015-11-06 修飾ｒｎａを含有する分子集合体及びそれを用いたｒｎａ送達システム

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-227611 2014-11-08
JP2014227611 2014-11-08

Publications (1)

Publication Number Publication Date
WO2016072500A1 true WO2016072500A1 (fr) 2016-05-12

Family

ID=55909223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2015/081352 Ceased WO2016072500A1 (fr) 2014-11-08 2015-11-06 Assemblage moléculaire contenant de l'arn modifié, et système d'administration de l'arn à l'aide de ce dernier

Country Status (2)

Country Link
JP (1) JP6586103B2 (fr)
WO (1) WO2016072500A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020070040A1 (fr) * 2018-10-01 2020-04-09 Johannes Gutenberg-Universität Mainz Particules d'arn comprenant de la polysarcosine
WO2020069718A1 (fr) * 2018-10-01 2020-04-09 Johannes Gutenberg-Universität Mainz Particules d'arn comprenant de la polysarcosine
RU2792644C2 (ru) * 2018-10-01 2023-03-22 Йоханнес Гутенберг-Университет Майнц Рнк-частицы, включающие полисаркозин
CN115926177A (zh) * 2022-11-11 2023-04-07 四川大学 一种聚合物、聚合物胶束及其制备方法和应用
CN116396465A (zh) * 2022-07-21 2023-07-07 苏州炫景生物科技有限公司 聚合物核酸递送载体及药物组合物应用
US12263215B2 (en) 2015-10-21 2025-04-01 BioNTech SE Cytotoxic immunostimulating particles and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031569A1 (fr) * 2006-09-11 2008-03-20 Max-Delbrück-Centrum für Molekulare Medizin Moyen permettant d'augmenter les niveaux intracellulaires de la protoporphyrine ix et utilisation correspondante
WO2012127739A1 (fr) * 2011-03-23 2012-09-27 国立大学法人岡山大学 Nouvelle molécule vectrice et nouveau procédé pour la libération de l'arn dans le cytoplasme à l'aide de lumière du proche infrarouge
WO2014038558A1 (fr) * 2012-09-04 2014-03-13 株式会社 島津製作所 Ensemble moléculaire utilisant un polymère à blocs amphiphile ramifié et système de transport de médicament

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008031569A1 (fr) * 2006-09-11 2008-03-20 Max-Delbrück-Centrum für Molekulare Medizin Moyen permettant d'augmenter les niveaux intracellulaires de la protoporphyrine ix et utilisation correspondante
WO2012127739A1 (fr) * 2011-03-23 2012-09-27 国立大学法人岡山大学 Nouvelle molécule vectrice et nouveau procédé pour la libération de l'arn dans le cytoplasme à l'aide de lumière du proche infrarouge
WO2014038558A1 (fr) * 2012-09-04 2014-03-13 株式会社 島津製作所 Ensemble moléculaire utilisant un polymère à blocs amphiphile ramifié et système de transport de médicament

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOGURE KENTARO ET AL.: "Multifunctional envelope-type nano device(MEND) as a non-viral gene delivery system", ADVANCED DRUG DELIVERY REVIEWS, vol. 60, no. 4-5, March 2008 (2008-03-01), pages 559 - 571 *
YAMAMOTO MASANAO ET AL.: "Improvement of the Efficacy of 5-aminolevulinic Acid-mediated Photodynamic Treatment in Human Oral Squamous Cell Carcinoma HSC-4", ACTA.MED.OKAYAMA, vol. 67, no. 3, 2013, pages 153 - 164 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12263215B2 (en) 2015-10-21 2025-04-01 BioNTech SE Cytotoxic immunostimulating particles and uses thereof
WO2020070040A1 (fr) * 2018-10-01 2020-04-09 Johannes Gutenberg-Universität Mainz Particules d'arn comprenant de la polysarcosine
WO2020069718A1 (fr) * 2018-10-01 2020-04-09 Johannes Gutenberg-Universität Mainz Particules d'arn comprenant de la polysarcosine
CN112867509A (zh) * 2018-10-01 2021-05-28 约翰内斯·古滕伯格美因兹大学 包含聚肌氨酸的rna颗粒
JP2022504141A (ja) * 2018-10-01 2022-01-13 ヨハネス グーテンベルグ－ウニヴェリジテート マインツ ポリサルコシンを含むｒｎａ粒子
RU2792644C2 (ru) * 2018-10-01 2023-03-22 Йоханнес Гутенберг-Университет Майнц Рнк-частицы, включающие полисаркозин
JP2024012419A (ja) * 2018-10-01 2024-01-30 ヨハネス グーテンベルグ－ウニヴェリジテート マインツ ポリサルコシンを含むｒｎａ粒子
AU2019353930B2 (en) * 2018-10-01 2025-03-06 BioNTech SE RNA particles comprising polysarcosine
US12419965B2 (en) 2018-10-01 2025-09-23 BioNTech SE RNA particles comprising polysarcosine
CN116396465A (zh) * 2022-07-21 2023-07-07 苏州炫景生物科技有限公司 聚合物核酸递送载体及药物组合物应用
CN116396465B (zh) * 2022-07-21 2024-02-13 苏州炫景生物科技有限公司 聚合物核酸递送载体及药物组合物应用
CN115926177A (zh) * 2022-11-11 2023-04-07 四川大学 一种聚合物、聚合物胶束及其制备方法和应用

Also Published As

Publication number Publication date
JP6586103B2 (ja) 2019-10-02
JPWO2016072500A1 (ja) 2017-08-17

Similar Documents

Publication Publication Date Title
Kanazawa et al. Nose-to-brain drug delivery system with ligand/cell-penetrating peptide-modified polymeric nano-micelles for intracerebral gliomas
Feng et al. Charge-convertible carbon dots for imaging-guided drug delivery with enhanced in vivo cancer therapeutic efficiency
Pelaz et al. Diverse applications of nanomedicine
Li et al. A composite hydrogel system containing glucose-responsive nanocarriers for oral delivery of insulin
JP6586103B2 (ja) 修飾ｒｎａを含有する分子集合体及びそれを用いたｒｎａ送達システム
US20230414529A1 (en) Proteinoid compounds, process of preparing same and uses thereof
Sigg et al. Stimuli-responsive codelivery of oligonucleotides and drugs by self-assembled peptide nanoparticles
US12377174B2 (en) Magnetic nanoparticles functionalized with N-(3,4-dihydroxyphenethyl)dodecanamide, production and use thereof
Meghani et al. Design and evaluation of clickable gelatin-oleic nanoparticles using fattigation-platform for cancer therapy
US20250222131A1 (en) Plasma-derived nanoparticles
CN102782573A (zh) 在治疗和诊断中应用的稀土掺杂上转换纳米颗粒
CN104902881A (zh) 包含金属微粒的静电结合型囊泡
Ryu et al. Elastin-like polypeptide for improved drug delivery for anticancer therapy: preclinical studies and future applications
Kim et al. pH-Sensitive carbon dots for enhancing photomediated antitumor immunity
WO2012118136A1 (fr) Sonde de nanoparticules fluorescentes de type à commutation, et procédé d'imagerie moléculaire de fluorescence l'utilisant
US12357702B2 (en) Peptidic diagnostic compositions
Lim et al. Lactosome-conjugated siRNA nanoparticles for photo-enhanced gene silencing in cancer cells
Barros et al. Branched amphipathic peptide capsules: different ratios of the two constituent peptides direct distinct bilayer structures, sizes, and DNA transfection efficiency
Kang et al. Self-assembled skin-penetrating peptides with controlled supramolecular properties for enhanced transdermal delivery
US10639371B2 (en) Thermoresponsive bioconjugates and their controlled delivery of cargo
Covarrubias-Zambrano et al. Development of a gene delivery system composed of a cell-penetrating peptide and a nontoxic polymer
KR101323848B1 (ko) 소수성 형광입자 및 광감작제-운반 폴리머좀 복합체
KR102574572B1 (ko) 알긴산-엽산 컨쥬게이트의 제조방법, 이로부터 제조된 알긴산-엽산 컨쥬게이트 및 이를 포함하는 약학 조성물
Wilson Tang et al. Design principles and biomedical applications of endoplasmic reticulum-targeting luminescent nanoparticles
KR101575710B1 (ko) 티올화 글리콜 키토산-거대분자 전송 도메인 복합체를 포함하는 안구질환 치료용 약물전달 시스템 및 그 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15857695

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016557827

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15857695

Country of ref document: EP

Kind code of ref document: A1